FDA Approves New Romidepsin Formulation for T-Cell Lymphoma Treatment

The U.S. FDA has granted approval to Amneal Pharmaceuticals for a ready-to-use romidepsin injection solution. This oncology medication is intended for adult patients with cutaneous T-cell lymphoma who have received previous systemic treatment. The new single-dose vial format is designed to enhance safety and streamline preparation in healthcare settings.